Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 10105 - 10112 of 12128 results

Business Judgment Rule Protects Board's Decision to Maximize the Value of an Insolvent Delaware Corporation Even If It Puts Creditors at Risk; But It Does Not Protect Transfers of Value from the Corporation to a Controlling Shareholder or Related Party

October 31, 2014| Alert| Viewpoint

FDA and the Center for Food Safety Reach Settlement Regarding FDA's GRAS Rule

October 30, 2014| Blog| Viewpoint

Where Did My Customer Go? Some Pleading Parameters for Tortious Interference

October 30, 2014| Blog| Viewpoint

How to Tailor Your Strategies for Engaging With Shareholder Activists

October 30, 2014| Blog| Viewpoint

Managing Antitrust Risks in Pre-Transaction Planning

October 30, 2014| Blog| Viewpoint

HHS Announces $840 Million Initiative to Improve Patient Care and Lower Healthcare Costs

October 30, 2014| Blog| Viewpoint

“Why, I declare” … Proper Use of Evidentiary Declarations under New (Post-AIA) Rule 37 C.F.R. 1.130

October 30, 2014| Advisory| Viewpoint

Office for Human Research Protections Releases Draft Guidance

October 29, 2014| Blog| Viewpoint

News & Press Releases

Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering

September 12, 2025

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement

September 12, 2025

Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.

Mintz Advises Premier Wealth Advisor Breed’s Hill Capital on Acquisition by Corient

September 12, 2025

Mintz represented Breed’s Hill Capital, a multi-family office overseeing approximately $3.5 billion in assets, in its acquisition by Corient, one of the nation’s leading wealth management firms. The transaction enhances Corient’s footprint in New England and advances its ability to deliver personalized fiduciary wealth management services across the region.

View all News and Press Releases